Bosulif belongs to a group of medicines known as tyrosine kinase inhibitors. Tyrosine kinases are proteins found in the body that control cell function, including cell growth.
Bosulif works by blocking the signal of certain tyrosine kinases, specifically Bcr-Abl tyrosine kinase, which stimulates the development of the abnormal blood cells that cause leukemia. By inhibiting the activity of Bcr-Abl kinase, Bosulif slows down or stops the production of the abnormal blood cells.
Bosulif is not approved for use in individuals younger than the age of 18, as it has not been adequately studied in this age group. Talk to your child's healthcare provider about the risks and benefits of using this medicine in children.
Older adults can use this medicine. In clinical trials, no differences were observed in the way older adults tolerated or responded to Bosulif compared with younger age groups. However, some older adults may be more sensitive to Bosulif side effects and, therefore, may need to be monitored more closely.
On occasion, your healthcare provider may recommend this medication for treating something other than the condition discussed in this article. This is called an "off-label" use. Using Bosulif to treat chronic myelogenous leukemia not associated with the Philadelphia chromosome is an example of an off-label use.